Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: TOLLIP

Gene summary for TOLLIP

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

TOLLIP

Gene ID

54472

Gene nametoll interacting protein
Gene AliasIL-1RAcPIP
Cytomap11p15.5
Gene Typeprotein-coding
GO ID

GO:0001775

UniProtAcc

B3KR28


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
54472TOLLIPHTA11_3410_2000001011HumanColorectumAD3.84e-021.91e-010.0155
54472TOLLIPHTA11_2487_2000001011HumanColorectumSER2.31e-095.08e-01-0.1808
54472TOLLIPHTA11_1938_2000001011HumanColorectumAD1.25e-033.77e-01-0.0811
54472TOLLIPHTA11_347_2000001011HumanColorectumAD1.16e-134.01e-01-0.1954
54472TOLLIPHTA11_411_2000001011HumanColorectumSER1.38e-026.16e-01-0.2602
54472TOLLIPHTA11_2112_2000001011HumanColorectumSER6.80e-034.06e-01-0.2196
54472TOLLIPHTA11_83_2000001011HumanColorectumSER3.87e-043.91e-01-0.1526
54472TOLLIPHTA11_696_2000001011HumanColorectumAD1.07e-072.94e-01-0.1464
54472TOLLIPHTA11_866_2000001011HumanColorectumAD8.33e-041.81e-01-0.1001
54472TOLLIPHTA11_1391_2000001011HumanColorectumAD3.91e-093.57e-01-0.059
54472TOLLIPHTA11_2992_2000001011HumanColorectumSER2.06e-054.11e-01-0.1706
54472TOLLIPHTA11_5212_2000001011HumanColorectumAD5.91e-032.68e-01-0.2061
54472TOLLIPHTA11_7696_3000711011HumanColorectumAD1.49e-082.38e-010.0674
54472TOLLIPHTA11_99999970781_79442HumanColorectumMSS1.95e-092.66e-010.294
54472TOLLIPHTA11_99999971662_82457HumanColorectumMSS1.03e-266.40e-010.3859
54472TOLLIPHTA11_99999974143_84620HumanColorectumMSS6.57e-062.26e-010.3005
54472TOLLIPLZE4THumanEsophagusESCC2.47e-139.21e-020.0811
54472TOLLIPLZE5THumanEsophagusESCC7.76e-031.02e-010.0514
54472TOLLIPLZE7THumanEsophagusESCC2.51e-091.05e-010.0667
54472TOLLIPLZE8THumanEsophagusESCC5.99e-111.48e-010.067
Page: 1 2 3 4 5 6 7 8 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
Colorectum (GSE201348)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.FAP: Familial adenomatous polyposis
CRC: Colorectal cancer
Colorectum (HTA11)The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AD: Adenomas
SER: Sessile serrated lesions
MSI-H: Microsatellite-high colorectal cancer
MSS: Microsatellite stable colorectal cancer
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:1903320ColorectumADregulation of protein modification by small protein conjugation or removal86/3918242/187239.43e-084.65e-0686
GO:0036010ColorectumADprotein localization to endosome12/391824/187231.48e-031.25e-0212
GO:19033201ColorectumSERregulation of protein modification by small protein conjugation or removal70/2897242/187236.84e-084.42e-0670
GO:1903322ColorectumSERpositive regulation of protein modification by small protein conjugation or removal34/2897138/187233.30e-032.83e-0234
GO:00360101ColorectumSERprotein localization to endosome9/289724/187237.19e-034.99e-029
GO:19033202ColorectumMSSregulation of protein modification by small protein conjugation or removal82/3467242/187237.49e-094.63e-0782
GO:00360102ColorectumMSSprotein localization to endosome12/346724/187234.68e-045.50e-0312
GO:1903320111EsophagusESCCregulation of protein modification by small protein conjugation or removal181/8552242/187231.80e-202.60e-18181
GO:001820514EsophagusESCCpeptidyl-lysine modification259/8552376/187233.90e-205.26e-18259
GO:190332216EsophagusESCCpositive regulation of protein modification by small protein conjugation or removal99/8552138/187234.39e-101.16e-0899
GO:001692512EsophagusESCCprotein sumoylation41/855253/187232.49e-062.86e-0541
GO:00360106EsophagusESCCprotein localization to endosome18/855224/187233.43e-031.41e-0218
GO:00332331EsophagusESCCregulation of protein sumoylation18/855225/187237.04e-032.56e-0218
GO:0033235EsophagusESCCpositive regulation of protein sumoylation10/855212/187238.94e-033.12e-0210
GO:190332012LiverCirrhoticregulation of protein modification by small protein conjugation or removal105/4634242/187231.43e-107.43e-09105
GO:00182051LiverCirrhoticpeptidyl-lysine modification134/4634376/187231.29e-062.59e-05134
GO:19033222LiverCirrhoticpositive regulation of protein modification by small protein conjugation or removal52/4634138/187234.91e-043.94e-0352
GO:00705553LiverCirrhoticresponse to interleukin-152/4634143/187231.27e-038.54e-0352
GO:0071347LiverCirrhoticcellular response to interleukin-141/4634113/187234.08e-032.19e-0241
GO:190332022LiverHCCregulation of protein modification by small protein conjugation or removal167/7958242/187234.99e-174.72e-15167
Page: 1 2 3 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa04620Oral cavityOSCCToll-like receptor signaling pathway58/3704104/84658.77e-031.98e-021.01e-0258
hsa046201Oral cavityOSCCToll-like receptor signaling pathway58/3704104/84658.77e-031.98e-021.01e-0258
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
TOLLIPSNVMissense_Mutationnovelc.230N>Ap.Cys77Tyrp.C77YQ9H0E2protein_codingdeleterious(0)probably_damaging(1)TCGA-2W-A8YY-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinCR
TOLLIPSNVMissense_Mutationc.325N>Tp.Pro109Serp.P109SQ9H0E2protein_codingtolerated(0.05)probably_damaging(0.981)TCGA-AA-3492-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownSD
TOLLIPSNVMissense_Mutationrs773801820c.74N>Tp.Thr25Metp.T25MQ9H0E2protein_codingdeleterious(0.03)benign(0.009)TCGA-AD-6964-01Colorectumcolon adenocarcinomaMale<65III/IVChemotherapyfolfoxPD
TOLLIPSNVMissense_Mutationc.109N>Ap.Ala37Thrp.A37TQ9H0E2protein_codingtolerated(0.31)benign(0.269)TCGA-CK-4947-01Colorectumcolon adenocarcinomaFemale<65III/IVOther, specify in notesfolinicSD
TOLLIPSNVMissense_Mutationc.714G>Tp.Gln238Hisp.Q238HQ9H0E2protein_codingtolerated(0.14)benign(0.046)TCGA-CM-4746-01Colorectumcolon adenocarcinomaMale<65I/IIUnknownUnknownSD
TOLLIPSNVMissense_Mutationnovelc.84N>Tp.Gln28Hisp.Q28HQ9H0E2protein_codingtolerated(0.09)benign(0.342)TCGA-AJ-A3EK-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIChemotherapycarboplatinCR
TOLLIPSNVMissense_Mutationnovelc.57N>Tp.Gln19Hisp.Q19HQ9H0E2protein_codingtolerated(0.16)benign(0.007)TCGA-AJ-A8CW-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
TOLLIPSNVMissense_Mutationnovelc.331N>Tp.Gly111Cysp.G111CQ9H0E2protein_codingdeleterious(0)probably_damaging(0.999)TCGA-AP-A05O-01Endometriumuterine corpus endometrioid carcinomaFemale>=65I/IIChemotherapycarboplatinPD
TOLLIPSNVMissense_Mutationrs552271777c.619G>Ap.Ala207Thrp.A207TQ9H0E2protein_codingtolerated(0.28)benign(0.001)TCGA-AX-A06F-01Endometriumuterine corpus endometrioid carcinomaFemale<65III/IVChemotherapycarboplatinSD
TOLLIPSNVMissense_Mutationrs368124186c.748N>Tp.Arg250Cysp.R250CQ9H0E2protein_codingdeleterious(0)probably_damaging(0.996)TCGA-B5-A3FC-01Endometriumuterine corpus endometrioid carcinomaFemale<65I/IIUnknownUnknownSD
Page: 1 2 3 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
54472TOLLIPKINASEacetylcysteineACETYLCYSTEINE
Page: 1